The HEBP2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colorectal adenocarcinoma cell line, featuring targeted disruption of the HEBP2 gene. This product provides a heterogeneous knockout pool, enabling functional studies of HEBP2 in a near-native genetic background without clonal selection bias. The CRISPR/Cas9 system introduces targeted gene modifications, and the resulting polyclonal population is suitable for a range of cellular and molecular assays to investigate HEBP2 function.
HT29 cells were originally isolated from a primary colon adenocarcinoma of a 44-year-old Caucasian female, and they are extensively used as a model system for colorectal cancer research. These adherent epithelial cells retain characteristic features of colon carcinoma, including the ability to differentiate under specific culture conditions. The HT29 line is valued for its reproducible growth properties and its utility in studying tumor biology, drug response, and signal transduction pathways relevant to colorectal malignancy.
HEBP2 (Heme Binding Protein 2) is a putative intracellular heme-binding protein implicated in the regulation of oxidative stress responses and apoptotic signaling. It functions within the intrinsic apoptotic pathway, acting downstream of TP53 transcriptional activation and oxidative stress stimuli. HEBP2 engages with BCL2 family members such as BCL2 and BAX to modulate mitochondrial outer membrane permeabilization, facilitating the release of cytochrome c and subsequent activation of caspase-9, which then propagates the caspase cascade, including caspase-3. Therefore, HEBP2 serves as a mediator linking cellular stress signals to mitochondrial-dependent cell death execution.
In the context of HT29 colon adenocarcinoma cells, disruption of HEBP2 is expected to impair intrinsic apoptotic signaling, potentially conferring reduced sensitivity to apoptosis-inducing agents such as chemotherapeutics or targeted therapies that engage the mitochondrial death pathway. This polyclonal knockout model enables researchers to dissect the contribution of HEBP2 to apoptosis resistance, a hallmark of colorectal cancer. By compromising the axis from HEBP2 to cytochrome c release and caspase-9 activation, these cells provide a valuable platform to study mitochondrial dysfunction and apoptotic dysregulation in a disease-relevant cellular environment.
HEBP2 knockout HT29 polyclonal cells are well-suited for mechanistic investigations of apoptosis regulation and for drug discovery efforts aimed at restoring apoptotic competence in colorectal cancer. Typical applications include comparing apoptotic responses between wild-type and HEBP2-disrupted cells via western blotting for cleaved caspases and cytochrome c, flow cytometric annexin V staining, and cell viability assays under various stimuli. They also support co-culture or long-term functional studies exploring HEBP2 interactions with BCL2, BAX, and upstream regulators such as TP53. For additional details, technical support, or custom inquiries, please contact Ascent Research.
